

ANNUAL REPORT

2023



Content

2023 Trans Tasman Radiation Oncology Group (TROG) Annual Research Report

Our Mission and Values	3
About TROG Cancer Research	4
2023 Facts and Figures	5
Message from the President and Board Chair	6
Message from the CEO of TROG	7
Finance Report	8
Message from the Finance Audit & Risk Management Committee	9
Message from the Chair of the TROG Scientific Committee	10
Research Highlights	12
Content Development Workshop	12
TROG 15.03 FASTRACK II Results	13
FASTRACK II Consumer Experience	14
TROG Clinical Trial Resource Development	15
2023 Publications	16
TROG Cancer Research Organisational Structure	18
Board of Directors	19
Services	22
Membership	23
Facility Alliance Membership	23
2023 Annual Scientific Meeting	25
Consumer Engagement	27
Fundraising and Events	28
2023 Study Portfolio	30
Recruiting Trials	32
Trials in Follow-up	35
Trials with TROG Involvement and Support	37
Sponsors	39
2023 TROG Committee Members	44



our **mission**

To conduct world-class research in radiation medicine that leads the global effort to better control and cure cancer. We are helping improve outcomes for people affected by cancer, through the conduct of high quality, practice changing clinical trials.

our **values**

Collaboration:

We will work with key stakeholders, organisations and community groups who share our aim of defeating cancer.

Quality:

Our research is guided by rigour, accuracy and innovative methodology.

Care:

We provide the utmost care and consideration to clinical trial participants. TROG Cancer Research members, staff and the general community.

Equity:

We strive to improve access and participation in clinical trials.

Innovation:

By being innovative in our research and embracing new technologies, we aim to be a leader in radiation medicine research.

about

TROG CANCER RESEARCH

The Trans Tasman Radiation Oncology Group (TROG) is steadfast in its commitment to revolutionise the delivery of radiation therapy for cancer patients through high quality scientific research, rigorous clinical trials, and the adoption of cutting-edge technology. Our primary focus is on refining radiation medicine technology applicable across a broad spectrum of cancers treatable with radiation therapy. Regarded as one of the principal modalities alongside chemotherapy and surgery, radiation therapy is a cornerstone in the fight against cancer. Approximately one in two individuals diagnosed with cancer could benefit from radiation therapy during their treatment journey. Radiation therapy employs precisely targeted and controlled doses of radiation to eradicate cancer cells or inhibit their ability to grow, disperse, or both. The administration typically involves targeted high-energy radiation beams, with ongoing research perpetually enhancing the methodologies and technological advancements utilised in treatment.

Since its inception 34 years ago in 1989, TROG Cancer Research has emerged from a collaborative initiative among members from seven radiation therapy centres across Australia and New Zealand into a pioneering clinical trials group. TROG Cancer Research is dedicated to the progression of studies on cancers amenable to radiation therapy treatments. With a founding vision centred on enhancing the lives of those affected by cancer through cutting-edge research in radiation medicine, TROG has fostered collaborations with a wide array of stakeholders, organisations, and community groups united by the common goal of conquering cancer.

Over the years, TROG has evolved into one of the preeminent collaborative clinical trials groups in Australia and New Zealand. Our network extends to members, hospitals, universities, government agencies, and other clinical trial groups, all working collectively to conduct crucial cancer research for the benefit of the community. To date, TROG has orchestrated more than 140 clinical trials, with the assistance of over 15,000 clinical trial participants: contributing to more effective treatments and enhancing quality of life for those with cancer both in Australia and globally. This collaborative effort has markedly improved cancer prognosis, elevating survival rates from below 50% in the 1980's to as high as 90% for certain cancers today.

TROG's comprehensive research spans an international network of over 1,600 healthcare professionals and more than 190 sites worldwide. Our extensive trial portfolio covers research into all tumour sites treatable with radiation, yielding outcomes that have precipitated shifts in clinical practice. These advances introduce new and refined radiation medicine techniques, elevating patient outcomes significantly.

Our research diligently focuses on radiation therapy for a myriad of cancer types, including but not limited to breast, lung, prostate, skin, brain and head and neck cancers. As a predominant cancer treatment modality, radiation therapy employs high-energy x-rays to control, and in many cases, cure various cancers. Through relentless pursuit of innovation, TROG continues to drive forward the boundaries of radiation therapy techniques, ensuring the delivery of the most advanced and effective treatments to those in need.

Trans-Tasman Radiation Oncology Group Limited Australian Charities and Not-for-profits Commission
Registered charity ABN:45132672292

TROG CANCER RESEARCH

2023 FACTS AND FIGURES



MEMBERSHIP

- 1681 Total members
- 196 Full members
- 1476 Affiliate members
- 9 Life members



FACILITY ALLIANCE MEMBERS

26 Facility Alliance Members across Australia and New Zealand



PARTICIPANTS IN TROG TRIALS

- 230 participants in 2023
- 15,349 since inception



CONFERENCE PRESENTATIONS

18 TROG conference presentations in 2023



PUBLICATIONS

11 TROG publications in 2023

message from the **President and Board Chair**



Professor Trevor Leong

It is with a touch of sadness that I pen this annual report as it will be my last as the President of TROG Cancer Research. I completed my tenure as President at the 2024 ASM in March, which took place in Newcastle.

The past year has been extremely busy for everyone at TROG. One of the major highlights was, of course, the ASM that was held in Adelaide. TROG has not hosted a meeting in Adelaide since 2011, so it was a timely return particularly with the impending opening of the Bragg Centre for Proton Therapy. The meeting was a wonderful opportunity to reunite our membership for four days of scientific exchange, networking, and social interaction under this year's conference theme of Accelerating Forward. The ASM requires a major effort to organise, and I would like to extend a big thank you to our convenors Prof. Hien Le, Ms. Kelly Skelton and Ms. Lydia Tamblyn, who together with the Organising Committee crafted the superb scientific and social programs that all attendees enjoyed.

For the TROG Board, 2023 has been a year of consolidation and reflection as we navigate the challenging times ahead for our organisation. As with other trial groups, TROG needs to operate as a sustainable business with robust governance structures to manage our finances, engage our members and partners, and continue our core business of running clinical trials. With this in mind, we have made strategically targeted appointments over the past three years to equip the Board with the necessary corporate skills and experience to take the organisation forward. For example, we recently appointed Mr. Andrew Beck, a corporate lawyer, and Mr. Murray McLachlan, an experienced patient advocate, as Independent Directors; both have already made valuable contributions during their first year as Directors. The Board also welcomed Dr. Gerry Adams as the incoming Dean of RANZCR FRO. Gerry brings a unique and valuable perspective to Board discussions as a Radiation Oncologist who practices in the private and regional sectors.

Each year, the Board convenes an Annual Board Strategic Planning Workshop, which allows us to monitor our performance against the strategic plan. This year, the Board, together with critical internal and external stakeholders, met in Sydney for an in-person workshop to develop the next Strategic Plan for 2024-2026. The workshop was facilitated by an external expert facilitator with many years of experience working with leading organisations across ANZ and the UK.

In addition to Board Directors and key TROG staff, participants also included representatives from key external organisations including National Health and Medical Research Council Clinical Trials Centre Genomic Clinical Cancer Trials Initiative (NHMRC CTC GCCTI), Cooperative Trials Group for Neuro-Oncology (COGNO), Psycho-Oncology Co-operative Research Group (POCOG) and the Medical Oncology Group of Australia (MOGA). The workshop identified common themes and strategies that will allow us to develop a meaningful and realistic strategic plan to guide TROG for the next three years.

TROG has enjoyed a very productive year, and I am very proud of all our staff for their significant achievements, which will be described in greater detail in the CEO, TROG Scientific Committee (TSC) Chair and Finance Audit & Risk Management Committee (FARM) Chair reports. Some of the highlights over the past 12 months include successful face-to-face ASM with over 200 registrants; continuing trial activity with 32 open trials, 10 trials in development, and over 15,000 participants recruited from 140 clinical trials over our 34-year history; new investigator-initiated trials developed collaboratively with other Cancer Collaborative Trials Groups; convening of our second Concept Development Workshop that was particularly successful in attracting new researchers to TROG; awarding of the second RANZCR TROG research grant that supports early career researchers in conducting secondary data analysis research projects.

On behalf of the Board of Directors, I would like to express my sincere thanks to all TROG staff, members, friends, supporters and collaborative partners for their hard work and support in 2023. I would also like to acknowledge all of our Facility Alliance Members for their generous support, without which TROG would not be able to continue its work as one of the world's premier cancer trials groups. From humble beginnings over 34 years ago, our organisation has built an enviable reputation in cancer research, and our brand name is well-known and respected internationally. Recognising our importance on the global stage, I was invited to give a presentation on behalf of TROG during the Presidential Symposium at the 2023 American Society for Radiation Oncology (ASTRO) meeting in San Diego, alongside distinguished leaders from NRG, European Organisation for Research and Treatment of Cancer (EORTC) and International Atomic Energy Agency (IAEA).

As I complete my term as TROG President, I would like to personally thank my fellow Board Directors for their commitment, guidance and friendship over the years. I am excited to hand the reins to A/Prof. Puma Sundaresan. Puma possesses exemplary leadership qualities and is passionate about our organisation. I do not doubt that TROG will flourish under her leadership.

message from the Chief Executive Officer



Ms. Susan Goode

As the CEO of TROG Cancer Research, I am delighted to share the accomplishments and progress our dedicated team, members and community have made over the past year. 2023 was a year marked by significant advancements, strengthening collaborations, and expanding our research impact on a global scale.

This year, our multidisciplinary membership continued to grow to over 1,600, with 196 Full members, 1,476 Affiliate members, and 9 Life members, demonstrating the increasing engagement and commitment within our community. We continued to have great support for our Facility Alliance Members with 26 hospitals and cancer treatment centres partnering with us, showcasing the dedicated network of support and collaboration across Australia and New Zealand.

A highlight of the year was our Annual Scientific Meeting (ASM) held in Adelaide. This event was a testament to our commitment to innovation and excellence in radiation medicine, bringing together over 200 registrants for four days of scientific exchange and networking. The successful organisation of this event was made possible thanks to the dedication of our convenors, the Organising Committee, and our industry partners, highlighting the importance of collaboration and community in our work.

In terms of research, TROG continued to lead and support impactful clinical trials, with over 15,000 participants recruited from 140 clinical trials over our 34-year history. Our study portfolio includes groundbreaking trials like TROG 15.03 FASTRACK II, which has positioned Stereotactic Ablative Body Radiotherapy (SABR) as a new standard of care for those with inoperable primary kidney cancer. These trials not only contribute to the advancement of radiation medicine but also have a direct impact on improving patient outcomes for those affected by cancer.

Financially, we have made strides towards sustainability, with a notable improvement in our deficit compared to the previous year. This financial stability allows us to continue our mission and expand our research efforts.

Looking forward, we are excited to embark on the development of our next Strategic Plan for 2024 - 2026. This plan will guide our efforts to continue leading in radiation medicine research, fostering innovation, and improving cancer outcomes on a global scale.

I am immensely proud of what we have achieved together this year. Our progress is a direct reflection of the hard work, dedication, and passion of our staff, members, partners, and the broader TROG community. As I reflect on the past year, I am filled with gratitude for the support and contributions from everyone involved.

Thank you to all our staff, members, friends, supporters, collaborative partners and clinical trial participants for your continued commitment to TROG Cancer Research. Your efforts are making a significant difference in the lives of those affected by cancer, and I look forward to what we will accomplish together in the coming year.



Finance Report



Doctor Tim Kuypers


TROG Cancer Research delivered a deficit of \$133,746 for 2023, a material improvement on the 2022 result.

Revenue grew by 15% to \$3.0 million with Research Services, Radiation Therapy Quality Assurance (RTQA) and Collaborative Group services all enjoying double digit growth. There was material increase in fundraising revenue due to the very successful Trek4TROG. The strong revenue result also benefited from favourable exchange and interest rate movements.


There was a 10% increase in expenditure to \$3.1million, impacted by high inflation and wage growth in the economy. The majority of the increase was due to employment expense growth which occurred because of both an increase in staff levels to meet the increased workload and wages growth. There were also increases in travel and other administrative costs as TROG returned to a more normal operating environment post the pandemic.

The deficit generated in 2023 reduced TROG's accumulated surplus (reserves for meeting future obligations and challenges) by 9%. However, the reserves remain above pre-pandemic levels.


Annual Surplus/Defecit




Revenue



Total Expenditure



Accumulated Surplus



message from the

Finance Audit & Risk Management Committee

Doctor Tim Kuypers

The focus of the Finance Audit & Risk Management Committee (FARM) in 2023 remained on the efficiency of the core business.

The FARM, a subcommittee of the board, continued to assist management in understanding financial performance at a trial level. A particular focus was placed on understanding TROG's time commitment for each trial. A better understanding of trial by trial, time requirements has allowed improvements in resource management. This more granular focus also allows the early identification of trials that are financially struggling and facilitates a mature discussion with investigators on the best ways to improve trial performance. This approach continues to improve TROG's financial outcomes, and we thank the investigators for entering these trial-based discussions in an open and constructive manner. The trial level financial analysis also assists in pricing TROG's work and will provide a solid basis for improving fee for service financial performance in the coming years.

I would like to thank the TROG team for their efforts and hard work over the year. I would also like to acknowledge my fellow FARM members and particularly thank Dr. Fiona Hegi-Johnson who retires from the FARM in 2024, for her valuable insights over a number of years.

message from the **Chair of the TROG Scientific Committee**



Associate Professor Sasha Senthil

2023 saw TROG Cancer Research enjoy a busy and productive year.


- Results of TROG 15.03 FASTRACK II (see page 13), TROG 17.02 OTRUN and TROG 13.01 SAFRON II were presented at a major international meeting.
- Dr. Joseph Sia was appointed the TROG representative to the GCCTI.
- **11** manuscripts published relating to TROG studies.
- **230** participants were recruited, bringing the overall accrual on TROG trial to 15,349
- Continuing trial activity with 32 open trials and 10 trials in development
- TROG 12.01 HPV OROPHARYNX achieved completion of follow-up for all participants (Trial Chairs: Prof. Danny Rischin, Peter MacCallum Cancer Centre VIC and Prof June Corry, St Vincent's Hospital VIC)
- **Six** new trial proposals submitted (4 Cat A | 2 Cat B),
- **Four** trial proposal accepted for development (Cat A; TD 23.01 REMASTER, TD 23.02 & TD 23.03 2SHOTS | Cat B; TD 23.04 PEARLS)
- The conduction of the TROG Concept Development Workshop, 31 May 2023 (see page 12 for further information)
- The TROG New Techniques and Technologies Committee (NTTC) developed a range of guidelines, resources and policies for TROG clinical trials via three sub/working groups (see page 12 for further information).
- The Independent Data and Safety Monitoring Committee (IDSMC) met twice in 2023 (03 May and 17 October) and reviewed nine TROG trials.

The TROG Scientific Committee (TSC) welcomed A/Prof. Peter Gorayski in March as the new discipline representative for radiation oncology. Peter has extensive clinical experience in the treatment of a broad range of cancers, with particular interest in brain cancer, head and neck cancer, sarcoma, skin cancer and prostate cancer and has a strong research interest in brain and prostate tumours, as well as proton therapy and artificial intelligence in radiation oncology. He serves as a staff specialist at the Royal Adelaide Hospital, Icon Cancer Centre and the Australian Bragg Centre for Proton Therapy and Research and holds an academic appointment as Associate Professor at the University of South Australia.

TROG and the Scientific Committee have continued working closely with our members to ensure that our trials and new proposals address the key priorities in radiation oncology and that we are horizon scanning for emerging technologies and techniques in radiation medicine. The TROG Working Parties are vital in shaping the research priorities of TROG by identifying gaps in research, developing new research concepts, reviewing the scientific merit of research proposals, and providing expert advice. Our tumour stream Working Parties are comprised of members from many craft groups and disciplines, with a focus on Breast; Central Nervous System (CNS); Genitourinary (GU); Head, Neck & Skin (HNS); and Lung cancers.

The Working Parties are complimented by several committees and special interest groups, who guide the TSC:

- **Secondary Data Analysis Committee (SDAC):** Oversees the development of guidelines and procedures for secondary analysis of TROG clinical trials data.
- **New Technologies and Techniques Committee (NTTC):** Ensures that up-to-date guidelines and procedures are available for implementing new and complex technologies in TROG clinical trials.
- **Independent Data and Safety Monitoring Committee (IDSMC):** Monitors progress of all TROG phase III and late phase II clinical trials in relation to quality processes and procedures and ensures the safety of patients and that, wherever possible, each trial meets its primary objectives.
- **TROG Publications Committee (TPC):** Provides peer review in the form of independent scientific review of publication material and timelines, helping to maintain high standards and encouraging accurate, thorough and credible research reporting of TROG clinical trials.
- **TROG Special Interest Groups (SIG):** Composed of TROG members who have an interest in clinical trial research involving specific technology or techniques in radiation oncology, current groups include Particle Therapy SIG, MR in Radiation Therapy SIG and Interventional Oncology SIG.



The participation of our members via these Working Parties, Special Interest Group's and committees brings incredible expertise, new ideas, partnerships, and collaborations in support of advancing radiation medicine research to improve outcomes for those affected by cancer.

The TSC and the chairs of the sub committees would like to thank those members who have stepped down from their committee roles- each of you has helped to shape the TROG Portfolio; Michael McKay (CNS WP), Kristy Robelo (GU WP), Gerry Hanna (Lung WP), Paul Nguyen (IDSMC), Nicolas Oddone-Baridon (IDSMC), Farshad Foroudi (NTTC), Benjamin Hindson (NTTC). It was fantastic to welcome 18 new members in 2023;

I would like to thank all members of the TSC for their enormous efforts during the year, particularly as much of this work is performed on a voluntary basis. My thanks also extend to the members of the various subcommittees that report to the TSC, including the five TROG Working Parties, New Techniques and Technologies Committee & subgroups, Independent Data and Safety Monitoring Committee, TROG Publications Committee, and the Secondary Data Analysis Committee.

If you would like to join a TROG committee, go to [surveymonky.com/r/TROG Join a Committee](https://surveymonky.com/r/TROG%20Join%20a%20Committee)

- Breast WP: Anelyn Chui (RT), Vikash Patel (RO) and Janice Yeh (RO)
- CNS WP: Peter Gorayski (RO), Hien Le (RO), Frank Saran (RO) and Joseph Sia (RO)
- GU WP: Eric Wegener (RO), Suki Gill (RO) and Michael Huo (RO)
- HNS WP: Bruce Ashford (Surgeon), Puma Sundaresan (RO), Eric Wegener (RO), Rathan Subramaniam (Radiologist and Nuclear Medicine Physician), Lessandra Yan Shan Chee (RO) and Clare Bajraszewski (RO)
- IDSMC: Lara Best (RO)
- NTTC: Lois Holloway (ROMP)
- SDAC: Dione Liefman (RO)

research Highlights

Concept Development Workshop

31st May 2023


TROG Cancer Research is excited to help support the new wave of researchers as they develop their concepts, with access to the TROG Working Parties and mentors for ongoing guidance. One of the ways TROG supports these researchers and ideas is by conducting Concept Development Workshops (CDWs).

Hosted by A/Prof. Puma Sundaresan (Convenor) and A/Prof. Sasha Senthil (Chair TROG Scientific Committee) along with Senior Research Fellows (Biostatistics) Mr. Chris Brown and Dr. Kristy Robledo, the 2023 online workshop was designed to support TROG's early to mid-career clinical cancer researchers develop their ideas into a trial concept.

Seven ideas were submitted to the 2023 CDW from TROG members of a variety of disciplines (Medical Physics, Radiation Oncology, Medical Oncology, Radiation Therapy) over a diverse range of subspecialties. Those ideas corresponded to a TROG subspecialty Working Party and received preliminary feedback prior to the CDW.

The CDW program was a mix of presentations on steps to develop a trial concept and trial design by Biostatisticians, Chris Brown and Kristy Robledo, and smaller group discussions, where each idea was workshopped in a multidisciplinary and collaborative manner. Every idea received input and guidance from experienced TROG trialists, their mentors and representatives from the National Technical Services for Quality of Life (Cancer Quality of Life Expert Service Team – CQUEST) and health economics (Cancer Research Economics Support Team - CREST).

TROG would like to thank Puma, Sasha, Kristy and Chris for conducting the workshop – we couldn't have done it without you! We would also like to give a big thanks to the mentors and faculty members for their time and guidance; Prof. Trevor Leong, Dr. Yu Yang Soon, Dr. Mark Pinkham, Prof. Martin Ebert, Dr. Meera Agar, Dr. Niluja Thiru, Prof. Brendan Mulhern (CQUEST) and A/Prof. Richard De Abreu Lourenco (CREST).





Practice Changing Clinical Trial Results for Kidney Cancer Patients

TROC 15.03 FASTRACK II Results

The FASTRACK II study represents a critical advancement in cancer research, responding to a concerning 78% increase in renal cell cancer diagnoses in Australia between 1993 and 2007. This study introduces Stereotactic Ablative Body Radiotherapy (SABR), a highly precise treatment for kidney cancer, challenging conventional approaches.

Initiated in 2016, FASTRACK II was designed to offer an alternative for patients who were not suited to surgery. This study was implemented across eight centres in Australia and the Netherlands to investigate the effectiveness of SABR and assess its associated side effects.

At the primary analysis, the trial enrolled 70 patients, with a median follow-up period of 43 months. The analysis findings were remarkable: 100% of treated kidney cancers showed no signs of recurrence, even in cases with an average tumour size of 4.6cm. Notably, only 10% of participants experienced significant treatment-related side effects, marking a noteworthy milestone in cancer care.

The study's success positions SABR as an excellent option, especially for patients with larger inoperable kidney tumours, where alternative treatments are limited.

Trial chairperson Prof. Shankar Siva said: "Stereotactic ablative body radiotherapy is a new standard of care for primary kidney cancer among those whose disease is not suited for surgery, and I believe the outcomes of our study support a future randomised trial comparing it with surgery for primary renal cell carcinoma."

The proposed next step involves comparing SABR to traditional surgery in patients with clearly operable tumours encouraged by the exceptional cancer control rates demonstrated by this international multicentre clinical trial. The prospect of comparing SABR to traditional surgery in a larger clinical trial holds immense potential in reshaping kidney cancer treatment strategies.

The FASTRACK II signifies a turning point in progress for the treatment of kidney cancer, presenting a compelling avenue for future advancements in radiation oncology.

FASTRACK II Consumer Experience

Charlie Sanders

Charlie Sanders, a 76-year-old resident of Rutherford, New South Wales, found himself thrust into the world of medical uncertainty when a routine ultrasound for aneurysms unexpectedly revealed a troubling growth on his kidney. Concerned, his GP wasted no time in referring him to a urologist for further investigation. Regular monitoring revealed that the haze on Charlie's kidney was continuing to grow and eventually reached a worrying size of 5.3cm. To make matters more challenging, Charlie's previous medical history meant that he was not a candidate for surgery.

Feeling like he was living with “a ticking time bomb”, Charlie's hope for a solution emerged when he was put forward as a candidate for the TROG 15.01 FASTRACK II Clinical Trial. “I was devastated to find out that the shadow on my kidney was inoperable, and then I found out about FASTRACK II trial which gave me new hope for treatment” he reflected.

Led by Prof. Shankar Siva, the aim of the study was to utilise high intensity radiation therapy technology to control the cancer within the kidney for patients where surgery is not an option. It would also monitor side effects, including potential to minimise effect on kidney function therefore avoiding ongoing dialysis. With little hesitation, and the full support of his wife Dianne, Charlie signed up for the trial.

A whirlwind of consultations, paperwork, and procedures marked Charlie's journey. From the initial biopsy to the series of three short treatments over the course of just one week, Charlie took each step in his stride. He soon found that side effects and disruption to his life were extremely minimal compared to what he had anticipated “With only three treatments on Monday, Wednesday and Friday of the same week, I was back at work and getting on with my day-to-day life” Charlie reflected in amazement.

After treatment, as the monitoring progressed, Charlie continued to charter new territory. His consultations with Prof. Jarad Martin, the overseeing physician, revealed the ultimate disappearance of the tumour that once threatened his well-being.

Now, seven years on, Charlie stands as a testament to the trial's success, his scans displaying 100% absence of the once-menacing growth.

The FASTRACK II results have been astonishing with many of trial participants experiencing no recurrence and all with minimal impact on their lives. This trial is practice changing, “Our study demonstrated that a novel treatment delivered in an outpatient setting is able to achieve unprecedented efficacy for patients with inoperable kidney cancer,” said trial chair Prof. Shankar Siva, “Thanks to Charlie and others like him, future patients with inoperable kidney cancer will now have access to SABR as standard of care in centres around the world.”

Charlie has expressed his gratitude not only to Prof. Siva and the medical team but also TROG Cancer Research for developing, sponsoring and coordinating FASTRACK II, as he acknowledges that these efforts orchestrated the trial that changed his life. Despite the uncertainty and challenges he faced, Charlie's resilience remained steadfast throughout. The trial not only provided him an alternative from surgery but also preserved his quality of life, allowing him to continue his daily activities without interruption and thereafter; with minimal damage to his kidney, Charlie has avoided any potential ongoing dialysis treatment.

As he looks back on his journey, Charlie's message resonates with gratitude and hope. The TROG 15.01 FASTRACK II Clinical Trial offers a beacon of hope for countless others facing similar diagnosis. Through his participation, Charlie had become a pioneer, contributing to the advancement of medical science for generations to come.



TROG Clinical Trial Resource Development

The TROG New Techniques and Technologies Committee (NTTC) had another very productive year. The NTTC frequently set up short term working groups, comprised of multi-disciplinary experts, to develop guidelines or policies to support TROG clinical trials. In 2023, three working groups developed a range of guidelines, resources and policies. The output of these groups is summarised below:

GROUP NAME	OUTPUT
Adaptive Working Group	<ul style="list-style-type: none">• TROG Adaptive Facility Questionnaire• TROG Adaptive Technical Framework• TROG Template: Radiation Therapy Planning, Delivery and Quality Assurance Guidelines (review and updates ongoing)
Medical Image Registration Working Group	Medical Image Registration Guideline for Trial Management Committees
Dosimetric Audit Working Group	TROG Policy for Independent Dosimetric Audits

We thank these groups for their incredible expertise and time spent developing invaluable resources for TROG clinical trials as well as the input and oversight of the New Techniques and Technologies Committee.

If you would like more information on the output from any of these groups, please contact the TROG [RTQA team](#).

our 2023 Publications

TRIAL OUTCOMES

TROG Led Studies

TROG 18.06 FIG

Barry N, Francis RJ, Ebert MA, Koh ES, Rowshanfarzad P, Hassan GM, Kendrick J, Gan HK, Lee ST, Lau E, Moffat BA, Fitt G, Moore A, Thomas P, Pattison DA, Akhurst T, Alipour R, Thomas EL, Hsiao E, Schembri GP, Lin P, Ly T, Yap J, Kirkwood I, Vallat W, Khan S, Krishna D, Ngai S, Yu C, Beuzeville S, Yeow TC, Bailey D, Cook O, Whitehead A, Dykyj R, Rossi A, Grose A, Scott AM. Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06. *Eur J Nucl Med Mol Imaging*. 2023 Aug 11. doi: 10.1007/s00259-023-06371-5. Epub ahead of print. PMID: 37563351.

Koh ES, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, Lau E, Khasraw M, Nowak AK, Bailey DL, Moffat BA, Fitt G, Hicks RJ, Coffey R, Verhaak R, Walsh KM, Barnes EH, De Abreu Lourenco R, Rosenthal M, Adda L, Foroudi F, Lasocki A, Moore A, Thomas PA, Roach P, Back M, Leonard R, Scott AM. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trial. *BMJ Open*. 2023 Aug 4;13(8):e071327. doi: 10.1136/bmjopen-2022-071327. PMID: 37541751; PMCID: PMC10407346.

Langen KJ, Galldiks N, Lohmann P, Mottaghy FM. Boosting the acceptance of 18F-FET PET for image-guided treatment planning with a multi-centric prospective trial. *Eur J Nucl Med Mol Imaging*. 2023 Nov;50(13):3817-3819. doi: 10.1007/s00259-023-06426-7. PMID: 37682302; PMCID: PMC10611633.

Collaborative Studies and Projects

TROG 21.12 ASPIRE

Khong J, Tee H, Gorayski P, Le H, Penniment M, Jessop S, Hansford J, Penfold M, Green J, Skelton K, Saran F. Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research. *J Med Imaging Radiat Oncol*. 2023 Dec 25. doi: 10.1111/1754-9485.13614. Epub ahead of print. PMID: 38146017.

TROG 14.02 RAIDER

Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung KC, Choudhury A, Foroudi F, Gribble H, Henry A, Hilman S, Hindson B, Lewis R, Muthukumar D, McLaren DB, McNair H, Nikapota A, Olorunfemi A, Parikh O, Philipps L, Rimmer Y, Syndikus I, Tolentino A, Varughese M, Vassallo-Bonner C, Webster A, Griffin C, Hall E. Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial. *Clin Oncol (R Coll Radiol)*. 2023 Sep;35(9):586-597. doi: 10.1016/j.clon.2023.05.002. Epub 2023 May 9. PMID: 37225552.

TROG 17.03 LARK

Sengupta C, Nguyen DT, Moodie T, Mason D, Luo J, Causer T, Liu SF, Brown E, Inskip L, Hazem M, Chao M, Wang T, Lee YY, van Gysen K, Sullivan E, Cosgriff E, Ramachandran P, Poulsen P, Booth J, O'Brien R, Greer P, Keall P. The first clinical implementation of real-time 6 degree-of-freedom image-guided radiotherapy for liver SABR patients. *Radiother Oncol*. 2023 Nov 24;190:110031. doi: 10.1016/j.radonc.2023.110031. Epub ahead of print. PMID: 38008417.

Secondary Data Analysis

TROG 3.04 RADAR

Ong, W. L., Nikitas, J., Joseph, D. J., Steigler, A., Denham, J. W., Millar, J. L., . . . Kishan, A. U. (2023). Patient-Reported Urinary and Bowel Quality of Life Outcomes Following External Beam Radiotherapy with or without High-Dose-Rate Brachytherapy Boost: Post-Hoc Analyses of TROG 03.04 (RADAR).. *Int J Radiat Oncol Biol Phys*, 117(2S), S93-S94. doi:10.1016/j.ijrobp.2023.06.424

Ong, W. L., Nikitas, J., Joseph, D., Steigler, A., Millar, J., Valle, L., . . . Kishan, A. U. (2023). Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR. *International Journal of Radiation Oncology Biology Physics*. doi:10.1016/j.ijrobp.2023.09.051

TROG 09.01 CHISEL

Bucknell NW, Kron T, Herschtal A, Hardcastle N, Irving L, MacManus M, Hanna GG, Moore A, Murnane A, Siva S, Ball D; CHISEL coauthors. Comparison of Changes in Pulmonary Function After Stereotactic Body Radiation Therapy Versus Conventional 3-Dimensional Conformal Radiation Therapy for Stage I and IIA Non-Small Cell Lung Cancer: An Analysis of the TROG 09.02 (CHISEL) Phase 3 Trial. *Int J Radiat Oncol Biol Phys*. 2023 Oct 1;117(2):378-386. doi: 10.1016/j.ijrobp.2023.04.009. Epub 2023 Apr 21. PMID: 37087060.

TROG 13.01 SAFRON II


Bucknell NW, Hardcastle N, Bressel M, Moore A, Montgomery R, Murnane A, Mai GT, Ball D, Kron T, Siva S; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II). *Int J Radiat Oncol Biol Phys*. 2023 Oct 21:S0360-3016(23)08005-7. doi: 10.1016/j.ijrobp.2023.09.052. Epub ahead of print. PMID: 37871885.

General

Nguyen H, Montgomery R, Sundaresan P. Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials. *J Med Imaging Radiat Oncol*. 2023 Jul 16. doi: 10.1111/1754-9485.13564. Epub ahead of print. PMID: 37454368.



TROG Cancer Research Organisational Structure



our

Board of Directors



Professor Trevor Leong

President/ Chairperson

MBBS, MD, FRANZCR

Radiation Oncologist and past Director of Division of Radiation Oncology, Peter MacCallum Cancer Centre; Director AGITG, Company Secretary AGITG.



Associate Professor Purnima Sundaresan

Full Member Director

MBBS, BSc (Hons), FRANZCR, GAICD, PhD

Consultant Radiation Oncologist Blacktown and Westmead Hospitals. Clinical Academic The University of Sydney, Associate Editor, Journal of Medical Imaging and Radiation Oncology, Chair Of Board of Head and Neck Cancer Australia.



Doctor Fiona Hegi-Johnson

Full Member Director

Chair, TROG Lung Working Party

Finance, Audit & Risk Management Committee

MBBS (Hons 1), BSc. Med (Hons)

Radiation Oncologist, Breast, Lung & SABR Service, Peter MacCallum Cancer Centre.

Senior Research Fellow, University of Melbourne.



Professor Annette Haworth

Full Member Director

FACPSEM, PhD, MSc, BSc (Hons)

Professor of Medical Physics, University of Sydney

Director, Institute of Medical Physics.

Life Member of TROG with more than 20 years serving on multiple clinical trials and TROG committees.

our

Board of Directors



Associate Professor Sashendra Senth

Full Member Director

Scientific Committee Chairperson

BHB, MBChB, PhD, MPH, FRANZCR

Radiation Oncologist Alfred Health Melbourne

Associate Professor Monash University.



Mrs. Susan Naeyaert

Independent Director

Finance, Audit & Risk Management Committee

BPharm, Grad Dip SC(Pharm) MCom

Over 20 years experience in pharmaceutical industry, in health economics, pricing and government policy. Experience in the US, Europe and Asia whilst having both Global and regional responsibilities.

European Organisation for Research and Treatment in Cancer (EORTC) use of Quality of Life instruments in randomised clinical trials.



Doctor Tim Kuypers

Independent Director

Finance, Audit & Risk Management Committee Chairperson

GAICD, PhD Economics, ACCA Diploma in Accounting and Finance.

Special Advisor at Houston Kemp Economists.

Member of Metro Trains Melbourne Board Safety Committee

Standards Board Australia.

Experienced non-executive director and senior executive.

Significant expertise in highly regulated industries of transport and telecommunications.



Doctor Melissa James

Full Member Director NZ

MBBS BSc (Hons) FRANZCR

Radiation Oncologist, Canterbury District Health Board New Zealand, Senior Lecturer at Otago University

our

Board of Directors



Mr. Andrew Beck

Independent Director

Finance, Audit & Risk Management Committee

Experienced in-house lawyer and General Counsel at Pacific National.

Experienced Director

Enjoys working with people to improve processes and develop strategies to generate valuable outcomes.



Mr. Murray McLachlan

Independent Consumer Representative Director

Deputy Chair of Cancer Voices NSW

Health Consumer NSW Board member.

Volunteered with Cancer Council NSW

Professional experience in the NSW public sector -policy and advocacy.

Personal cancer experience as both a person diagnosed with prostate cancer (successful treatment 2009) and as a long term partner and carer of a person diagnosed with pancreatic cancer (passing in 2007).



Doctor Gerry Adams

RANZCR FRO Director

Royal Australian and New Zealand College of Radiologist (RANZCR)

Representative MBBS, FRANZCR, MAICD

Consultant Radiation Oncologist for GenesisCare in Bundaberg QLD,

Dr Adams has helped develop and expand the service over the years

and has published several research papers, reviews and book

chapters, presented at national and international conferences and is

an active member of Faculty of Radiation Oncology, sitting on the

Quality Improvement committee.

our services

Transforming Cancer Care Through Research and Collaboration

1. Empowering Clinical Trials: Trial Management

At the heart of TROG Cancer Research is our Central Operations Office, a cornerstone of innovation and excellence in clinical trial management. From initial concepts to the impactful dissemination of results, our team ensures that every phase of trial coordination is executed flawlessly. Under Renee Swanson's leadership, we focus on meeting site activation and participant recruitment goals, safeguarding participant safety with a risk-based monitoring approach and ensuring data integrity and regulatory compliance. Our commitment extends beyond operations, providing vital support to Trial Chairpersons and Committees, fostering a collaborative environment for groundbreaking research.



2. Catalysing Research Innovation: Trial Development

Guided by Rebecca Montgomery, our Trial Development team is dedicated to nurturing high-impact cancer research trials. We provide an ecosystem where new ideas are developed into robust protocols through expert peer review and collaboration. Our comprehensive support includes everything from protocol and budget development to funding coordination and database development services, ensuring that innovative concepts transition smoothly from inception to implementation.



3. Assuring Quality and Precision: Radiation Therapy Quality Assurance

Led by Alisha Moore, our RTOA team sets the gold standard for data accuracy and protocol compliance, fundamental pillars for the credibility of clinical trial results. Through the development of risk-adapted quality assurance programs and the implementation of radiation therapy guidelines, we ensure the highest levels of trial integrity. Our proactive approach in monitoring, management, and horizon scanning underscores our commitment to maintaining and elevating global best practices in cancer research.



4. Fostering Global Partnerships: Collaborative Group Services

Our Collaborative Group Services extend TROG's reach beyond individual trials, offering comprehensive support for clinical research projects through expert grant administration, legal support, and regulatory compliance. This service ensures that our members have the resources and support needed to navigate the complexities of clinical research, enhancing our collective ability to drive meaningful advances in cancer treatment.


5. Driving Forward with Robust Support: Business Services

TROG Cancer Research's success is underpinned by our Business Services, which provide a solid foundation for our operational, financial, and engagement strategies. In 2023, we continued our partnerships with leading external organisations to enhance our capabilities in information technology, event management, financial and human resource management, and communications. These collaborations ensure our members are well-supported, well-informed, and fully engaged in our mission to conquer cancer.

our

Membership

20 TROG members in other countries



Key

-  TROG Members Australia and New Zealand
-  Facility Alliance Member Centres and Sites

Facility Alliance Membership is also represented throughout Australia and New Zealand by sites owned by GenesisCare and ICON Group Cancer Care.

Over 10% of our Membership comes from Rural/Regional/Remote Australia

FACILITY ALLIANCE MEMBERSHIP



The TROG Cancer Research Facility Alliance Membership (FAM) is one of the cornerstones of TROG's collaborative outreach, and for 2023, that certainly held true. With centres in every corner of Australia and New Zealand the strength of support of our FAM members, and TROG's provision of services in the area of Clinical Trial implementation continues to foster our shared goal of improving patient outcomes.

The TROG Central Operations Office is a hub of specialised IT support, expert advice and knowledge from sub-specialty groups, and our Radiation Therapy Quality Assurance team continues to provide expert services to our FAM partners.

Cancer Treatment Centres and Hospital Radiation Oncology Departments comprise our 26-strong group of facilities supporting TROG via the membership to conduct investigator-initiated scientifically robust clinical trials. The TROG 2023 ASM in Adelaide provided a perfect opportunity to celebrate the longevity of this initiative having passed the ten year milestone. Representatives from each of the FAM centres accepted certificates from CEO Susan Goode and we were able to capture the moment front and centre on stage at the Gala Dinner.

As always, TROG continues to extend gratitude to the facilities who maintained their place as a Facility Alliance Member throughout the 2023 calendar year, and we look forward to our continued partnership in 2024 and beyond.

DISCIPLINE	FULL AND LIFETIME MEMBERS	AFFILIATE MEMBERS	2023
RADIATION ONCOLOGISTS	156	185	341
RADIATION THERAPISTS	9	570	579
RADIATION ONCOLOGY REGISTRARS	5	147	152
TRIAL COORDINATORS/DATA MANAGERS	2	233	235
MEDICAL PHYSICISTS	13	85	98
MEDICAL ONCOLOGISTS	4	6	10
INTERVENTIONAL ONCOLOGISTS	1	8	9
STATISTICIANS	1	7	8
CONSUMERS/OTHER	14	235	249
TOTAL MEMBERSHIP	205	1476	1681

2023

Annual Scientific Meeting

We would like to sincerely thank Co-Convenors, Prof. Hien Le, Ms. Kelly Skelton and Ms. Lydia Tamblyn for welcoming TROG and our delegates to Adelaide and their commitment to bringing together the TROG 2023 Annual Scientific Meeting (ASM) from 19-22nd June.

This was also made possible by the organisation and event coordination provided by the team at Encanta Event Management. This was the second time their team hosted the event in-person, and it was great to see all their groundwork come to fruition.

In addition, we recognise the hard work of our Organising and Program Committees, who helped to orchestrate a seamless ASM event featuring insights from leaders in radiation medicine.

Across the four-day event, we were honoured to hear from over 75 speakers from Australia, New Zealand and further abroad about the ever-evolving landscape of cancer research and radiation medicine, palliative care, big data, artificial intelligence, machine learning, emerging technologies and so much more.

Among the list of speakers, we got to hear from Dr. Adam Holtzman (USA), Dr. Justin Baker (USA), Dr. Rhys Williams (Australia), A/Prof. Johan Verjans (Australia), Dr. Alex Dunn (New Zealand), Dr. Shohei Komatsu (Japan), Prof. Ryohei Sasaki (Japan) and more!

We are very appreciative of all our speakers who joined our event, virtually or in-person, from all corners of the world to share their work and developments in radiation medicine.

In addition to our workshops and plenary sessions, we had vast opportunities to network and connect with colleagues and other industry professionals while learning more about the work of our exhibitors and sponsors.

WORKSHOPS

Clinical Research Education Workshop

The 2023 workshop was structured as a training day to give the opportunity for attendees to dive deeper into topics such as source documentation, the study coordination process, managing remote activities and working as a team to get through day to day issues such as noncompliance, overwhelm in the workplace and onboarding of new staff. This session hosted by Eleanor Allan from Caledonian Clinical Training was interactive, welcoming, and structured to suit all levels of experience.

With over 45 attendees present on the day we have received some great feedback suggesting the attendees enjoyed the content and structure of the workshop.

Technical Research Workshop

With over 65 attendees, the Disney theme of this workshop highlighted the amazing and sometimes seemingly “magical” advancements in technology and treatments in radiation oncology.

There were many interesting talks, ranging from ethics in Artificial Intelligence, to TROG infrastructure needs, to the future of proton therapy clinical trials. In 2023 the Technical Research Workshop (TRW) included a panel discussion with live polling. Several delegates mentioned they enjoyed the panel discussion and would like to see this at future workshops.

TROG would like to thank the sponsor of the TRW, Varian, A Siemens Healthineers Company for their continued support of this fantastic educational event.



OUR 2023 EXHIBITORS & SPONSORS

TROG was excited to host a range of sponsors and exhibitors who were able to engage with key decision makers, demonstrating their products and services to delegates at TROG's premier event. If it weren't for our generous exhibitors and sponsors, we wouldn't have been able to host an ASM of this magnitude. We thank you for your commitment and support and look forward to continuing our partnership's into the future.

GALA DINNER

At our 'Disco' themed Gala Dinner, we were able to recognise the achievements of our team and the cancer research community for their hard work and commitment to cancer research. We also had a lot of fun with prizes for best dressed and best dance moves!

Prof. Peter Greer was awarded the 'Outstanding Contribution to Radiation Therapy Quality Assurance' award (sponsored by Radformation and Gamma Gurus) for his contributions to TROG's Radiation Therapy Quality Assurance program. Prof. Greer has been a long-standing member of the TROG New Techniques and Technologies Committee and was appointed as Chair of this Committee in 2015, serving for over 7 years.

This year our Attendance Grants supported members of the TROG community who provide health care to people located in regional, rural, and remote areas of Australia or New Zealand.

THANK YOU TO OUR PARTICIPANTS!

Lastly, but certainly not least, we are so appreciative of each and every one of the over 200 participants who attended our 2023 ASM. We hope you all enjoyed coming back together for our event and gained a lot of valuable insight from our range of speakers, hosted workshops and industry sponsors.



consumer Engagement

In 2023, TROG Cancer Research reaffirmed its commitment to consumer engagement, placing the voices of patients, individuals with lived experience, and the broader community at the forefront of our research endeavours. Our dedication to incorporating consumer perspectives has been crucial in defining our research priorities, refining trial designs, and enhancing outcomes for those affected by cancer. Supporting consumer involvement also brings a diverse array of experiences and insights into our research and is instrumental in reviewing and providing feedback on trial protocols to ensure they are patient-centred and meet real-world needs of our community.

TROG ensured that consumers played an active role in the running of our 2023 Annual Scientific Meeting (ASM). Their participation and insights emphasised the significance of patient and public involvement in cancer research, offering real-world perspectives that inspired our researchers and clinicians.

The feedback from our consumer engagement activities has directly shaped our research agenda. It has prompted the development of more accessible and understandable patient information materials, ensuring that trial participants are well-informed and supported throughout their journey.

We are grateful for the contributions of our consumer community and would like to especially thank:

- Sue McCullough, a long-term and highly valued consumer member, has significantly contributed to the Lung Working Party and has been instrumental in bringing consumer input to the forefront of our annual Clinical Research Education Workshop (CREW). Additionally, Sue provides a crucial consumer perspective on several TROG lung cancer clinical trials.
- John Stubbs, our dedicated consumer representative on the TROG Scientific Committee, continues to make invaluable contributions to consumer advocacy within our organisation and beyond. He is a regular participant in our ASM, offering consumer insights across numerous sessions.
- Murray McLauchlan, has served as the Independent Consumer Director on the TROG Board of Directors since 2022. Murray not only represents the consumer perspective at the board level but also facilitates consumer engagement in various TROG activities, including collaboration with Cancer Voices NSW to incorporate consumer input into new clinical research proposals.

As we look to 2024, our commitment to deepening consumer engagement remains steadfast. We plan to continue our dedication in placing patients at the centre of everything we do by enabling more consumers to participate in our tumour stream Working Parties, hosting a dedicated consumer panel session at future ASMs, and enhancing collaboration with consumer advocacy organisations. These initiatives will offer valuable forums for discussion and opportunities for consumers to engage in different aspects of our research.

Our efforts to involve consumers not only enrich our research but also ensure that we continue to make significant progress in controlling and curing cancer. We look forward to further strengthening our consumer partnerships in the years ahead.

2023

Fundraising and Events

Myall Lakes Veterans Club Golf Day fundraiser

The Myall Lakes Veterans have been supporters of TROG Cancer Research for almost ten years by way of an annual golf day fundraiser. On 2nd November 2023, 107 golfers tee'd off with a shotgun start at 11am, in the picture perfect location at Hawks Nest Golf Club, with perfect weather conditions to match.

All locals to the area, most participants have a special place for TROG's research having been affected by cancer and knowing that 1 in 5 men will be diagnosed with prostate or bowel cancer by their mid-80s. But let's not forget that the lady veterans (who play every Thursday themselves) also contributed to the fundraising event having completed a few rounds earlier that morning! The ladies' veterans are led by Fran Henderson, wife of the late Don Henderson, to whom we give special mention for establishing the clubs sole yearly fundraising event almost ten years ago. Sadly, Don passed away from cancer early in 2023, but we are glad that this very worthwhile tradition is not only upheld but continues to grow.

This year we give special thanks to President of the club Col Clinch, and club Secretary Peter Buttrey who were pivotal in driving the successful 2023 event. Peter is pictured here in action, and it's worth noting that this particular swing earned him "closest to the pin" on the day!

After an energetic day in the sun golfers made their way back to the club for the presentation where TROG CEO Susan Goode had the privilege of speaking to members on the impact of their donations to TROG.

This year the event raised an astounding \$4,000 which is a huge increase on previous years. All funds go directly to TROG to continue our important work and for that we cannot thank the Veterans enough for their unwavering, heartfelt and generous support. Special thanks also to Captain Peter Gurney, to the nine members of the veterans committee, and of course to the players themselves for making this such a successful and enjoyable day. Also, to the generous bidders of raffle prizes in the afternoon, and to the amazing local businesses that donated them, we thank you all.

We hope that this event will continue as not only a significant contribution to TROG but a wonderful opportunity for us at TROG Central Operations Office to connect with the communities impacted by our work. We hope to see you in 2024 for another successful event.

TREK4TROG 2023

The sun was hidden behind clouds and a gentle drizzle followed us on and off for the first few hours of our 20km Mount Kosciusko Trek on 2nd December 2023. The scenery was amazing with snow gums, breathtaking landscapes and wildflowers just begging us to take their photo. At Seamans Hut we sheltered and discussed the risks of getting caught in a thunderstorm but decided to make the dash to the top. The dash being three kms uphill walk to reach the peak. That was the hard bit but when we made it to the top of Mount Kosciuszko we were rewarded with sunshine. To be standing on top of Australia surrounded by stunning views and remarkable people was breathtaking.

The kindness of the weather was not to last and our guides gathered us for another dash back to Seamans Hut. It was downhill this time, and our legs certainly got some energy when the thunder let rip right around us. Sheltering at Seamans Hut as the hail passed us by, we then did the last seven kms back to our pickup point, with drizzle to heavy showers creating little rivers everywhere, encouraging us to get home to a hot shower and dry clothes.

The experience was fantastic, the comradery engaging, financial support tremendous and the organisers and guides exceptional. All together, we were able to raise over \$30,000. Watch this space to see where TROG heads off to in 2024 and be sure to put it in your calendar. It will be an experience not to be missed!




our

Study Portfolio

As of December 31st 2023

		CATEGORY				TOTAL
		A	B	C	D	
TRIAL STATUS	NEW PROPOSAL	2	1	0	0	3
	DEVELOPMENT	5	2	5	0	12
	START UP	0	0	1	0	1
	OPEN	13	5	11	0	29
	CLOSED	18	5	5	0	28
	COMPLETED	39	8	2	0	49
	DATA REQUESTED	0	0	0	25	25
	TOTAL	77	21	24	25	147

STUDY PORTFOLIO



	NEW PROPOSAL	DEVELOPMENT	START UP	OPEN	CLOSED	COMPLETED	DATA REQUESTED	TOTAL
BREAST	0	0	0	5	7	1	0	13
CNS	1	2	0	3	0	4	0	10
GI	0	1	1	4	2	12	2	22
GU	0	4	0	6	5	7	7	29
GYNAE	0	0	0	2	0	1	0	3
H & N	0	0	0	2	3	5	8	18
LUNG	1	2	0	2	3	2	6	16
LYMPHOMA	0	0	0	0	4	3	0	7
MULTIPLE	0	3	0	3	1	2	2	11
SKIN	1	0	0	2	2	4	0	9
SYMPTOM MANAGEMENT	0	0	0	0	1	8	0	9
TOTAL	3	12	1	29	28	49	25	147

our

2023 Recruiting Trials

SAHMRI/TROG 21.12 ASPIRE

A/Prof. Hien Le

Category A Multiple Cancer Types

Title: Australian Proton Therapy Clinical Quality Registry (ASPIRE)

Overview

ASPIRE is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. The aim of the ASPIRE registry is to enrol >5000 patients who have been treated with radiation therapy in order to better understand and compare the short and long-term benefits of the different types of radiotherapy. The information collected will help researchers learn more about radiation treatment.

Sponsor: South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research parent company)

Supporters: TROG Cancer Research

Funded by: Hospital Research Foundation Group grant

Status at 31/12/2023: Opened; 27 March 2022 | Sites activated; 1 | Accrual; 58

Registry: ANZCTR, ACTRN12622000026729

Website: sahmri.org.au/research/programs/registry-centre/groups/australian-particle-therapy-clinical-quality-registry-aspire

Study email: APTCQR@sahmri.com

TROG 21.07 SOCRATES HCC

A/Prof. David Pryor & Prof. Alan Wigg

Category A Gastrointestinal

Title: A randomised controlled trial of Standard Of Care versus RadioAblation in Early Stage HCC (SOCRATES HCC)

Overview

Hepatocellular carcinoma (HCC) has one of the fastest rising incidence and mortality rate of any cancer, however, treatment options remain limited and 5-year survival is poor. Unlike most other cancers, the majority of people presenting with early-stage HCC are unable to receive curative intent local therapies or may progress following initial treatment with thermal ablation or transarterial therapies. Emerging data supports a role for stereotactic ablative body radiotherapy (SABR) as a well-tolerated, non-invasive treatment with high rates of local control with some centres now considering it a new standard of care. However, randomised evidence comparing the various treatment options in the first line setting is lacking and the majority of guidelines do not currently endorse its use leading to highly variable utilisation around Australia and internationally. SOCRATES HCC seeks to address this evidence gap by comparing SABR to other current first line treatments (thermal ablation, transarterial therapies) for non-surgical candidates with solitary (≤ 5 cm) early-stage HCC.

SOCRATES HCC aims to set a new benchmark in the management of HCC, improving access to effective curative intent therapies and enhancing inter-disciplinary collaboration.

Sponsor: TROG Cancer Research

Collaborators: Australasian Gastro-Intestinal Trials Group (AGITG)

Supporters: Abdominal Radiology Group of Australia and New Zealand (ARGANZ) & Gastrointestinal Society of Australia (GESA)

Funded by: Medical Research Future Fund (RCRDUN | 2021)

Status at 31/12/2023: Opened; 10 October 2022 | Sites activated; 14 of 19 | Accrual; 31 of 218

Registry: ANZCTR, ACTRN12621001444875

Study email: SOCRATES_HCC@trog.com.au

TROG 20.01 CHEST RT

Dr. Eric Hau & Dr. Sagun Parakh

Category A Lung

Title: Chemotherapy and Immunotherapy in extensive stage small cell lung cancer with thoracic radiotherapy (CHEST RT)

Overview

CHEST RT is investigating the safety and effectiveness of combining chemotherapy and immunotherapy with chest radiation therapy for the treatment of extensive stage small cell lung cancer (ES-SCLC). For over 20 years, a combination of chemotherapy using etoposide with either cisplatin or carboplatin had been used to treat ES-SCLC. Adding immunotherapy to the chemotherapy combination has been shown to help boost the body's natural defences to fight cancer, improving response to treatment. This combination of chemotherapy with immunotherapy is now the standard of care treatment. Research has shown that radiation therapy also improves the ability of the immune system to recognise tumours. The researchers would like to investigate whether combining radiation therapy with the standard chemo/immunotherapy may further improve patients response to treatment.

Sponsor: TROG Cancer Research

Collaborators: Thoracic Oncology Group of Australasia (TOGA)

Funded by: AstraZeneca; (Externally Sponsored Scientific Research grant)

Status at 31/12/2023: Opened; 11 November 2021 | Sites activated; 8 of 8 | Accrual; 24 of 35

Registry: ANZCTR, ACTRN12621000586819

Study email: CHESTRT@trog.com.au

TROG 19.06 DECREASE

A/Prof. Shankar Siva & A/Prof. Arun Azad

Category A Genitourinary

Study Title: DarolutamidE + Consolidation RadiothErapy in Advanced proStatE cancer detected by PSMA

Overview

In the era of PET imaging, many sites of disease that are not visible on conventional imaging (such as CT scans) will be found on Prostate Specific Membrane Antigen (PSMA)-PET scans. These macroscopic sites of disease are the main cause of cancer progression after completing androgen deprivation therapy for prostate cancer. Darolutamide is an indicated treatment for men with Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC) with an increasing PSA level. Radiotherapy to sites of disease that have not completely resolved after a few months of drug therapy has been shown to improve patient outcomes, including longevity, in other cancers like lung cancer. With the evolution of PSMA PET scanning, in prostate cancer, there is a unique opportunity to replicate these findings in low-volume prostate cancer.

In 87 men with castration-resistant prostate cancer with no evidence of metastases on conventional imaging but detectable disease on PSMA-PET/CT scan, the DECREASE trial will compare the treatment outcomes of men taking Darolutamide with or without treating the small metastasis seen on the PSMA PET scan with RT. Led by A/Prof Shankar Siva and A/Prof Arun Azad, DECREASE aims to determine that the combination (Darolutamide + RT) is better than Darolutamide alone at controlling PSA levels and further spread of prostate cancer. The DECREASE trial, if successful, will meaningfully extend disease control in men receiving Darolutamide.

Sponsor: TROG Cancer Research

Collaborators: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Funded by: Bayer (investigator-initiated research grant).

Status at 31/12/2023: Opened; 02 June 2021 | Sites activated; 17 of 17 | Accrual; 52 of 87

Registry: ClinicalTrials.gov, NCT04319783

Study email: DECREASE@trog.com.au

TROG 18.06 FIG

A/Prof. Eng-Siew Koh & Prof. Andrew Scott

Category A CNS

Study Title: Prospective, multicentre trial evaluating FET-PET in Glioblastoma

Overview

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Sponsor: TROG Cancer Research

Sponsor: TROG Cancer Research

Collaborators: The Australasian Radiopharmaceutical Trials network (ARTnet) and The Cooperative Trials Group for Neuro-Oncology (COGNO)

Funded by: Medical Research Future Fund, Cure Brain Cancer Foundation and the Australian Brain Cancer Mission / Cancer Australia

Status at 31/12/2023: Opened; 14 December 2021 | Sites activated; 11 of 11 | Accrual; 166 of 210

Registry: ANZCTR, ACTRN12619001735145

Study email: FIG@trog.com.au

TROG 18.01 NINJA

Prof. Jarad Martin & Dr. Mark Sidhom

Category A Genitourinary

Title: Novel Integration of New prostate radiation schedules with adjuvant Androgen deprivation

Overview

In men with intermediate and high-risk prostate cancer, the NINJA trial is looking at comparing two different radiotherapy treatment schedules called stereotactic body radiotherapy (SBRT). The aim is to develop better methods of treatment for prostate cancer using this type of treatment, and further understand what causes some of the side effects of treatments. It is hoped this research will potentially improve the accuracy and quality of radiotherapy treatment in prostate cancer.

Sponsor: TROG Cancer Research

Collaborators: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Funded by: Investigator Initiated grant from Mundipharma, Cancer Australia grant, investigator funds and in-kind support from recruiting sites.

Status at 31/12/2023: Opened; 16 January 2019 | Sites activated; 19 of 21 | Accrual; 298 of 472

Registry: ANZCTR, ACTRN12618001806257

Study email: NinjaTrial@calvarymater.org.au

USYD/TROG 17.03 LARK

Dr. Yoo Young (Dominique) Lee & A/Prof. Tim Wang

Category A Multiple Primaries

Study Title: Liver Ablative Radiotherapy utilising Kilovoltage intrafraction monitoring (KIM)

Overview

Stereotactic Ablative Body Radiotherapy (SABR) is an established treatment for both primary and secondary liver malignancies and is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of Kilovoltage Intrafraction Monitoring (KIM) as a potential solution for real-time image guidance in liver SABR. It is hoped that this information will improve cancer targeting accuracy and lead to better patient outcomes in the future.

Sponsor: University of Sydney

Collaborators: TROG Cancer Research

Funded by: NHMRC

Status at 31/12/2023: Opened; 16 October 2019; Recruitment closed 31 December 2023 |

Sites activated; 7 of 7 | Accrual; 32 of 46

Registry: ClinicalTrials.gov, NCT02984566

Study email: LARK@trog.com.au

our

Trials with Participants in Follow-up in 2023

EORTC 22033-26033/TROG 06.01 Low Grade Glioma

Category B CNS

Study Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study

Lead Researcher: Dr. Claire Phillips

Primary Sponsor or Lead Organisation: EORTC (TROG)

Study email: TRIALS@trog.com.au

TROG 07.01 /BIG 3-07 DCIS

Category A Breast

Study Title: A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in-situ (DCIS) of the breast

Lead Researcher: Prof. Boon Chua

Primary Sponsor or Lead Organisation: TROG Cancer Research

Study email: DCIS@trog.com.au

TROG 08.06 STARS

Category A Breast

Study Title: A Randomised comparison of anastrozole commenced before and continuing during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy

Lead Researcher: Prof. Peter Graham

Primary Sponsor or Lead Organisation: TROG Cancer Research

Study email: StarsTrial@health.nsw.gov.au

TROG 12.01 HPV OROPHARYNX

Category A Head & Neck

Study Title: A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis loco regionally advanced HPV-associated oropharyngeal squamous cell carcinoma

Lead Researcher: Prof. Danny Rischin & A/Prof. June Corry

Primary Sponsor or Lead Organisation: TROG Cancer Research

Study email: Juliana.Dilulio@petermac.org (study closed 06/10/2023)

TROG 12.02 PET LABRADOR

Category A Breast

Study Title: PET scans for locally advanced breast cancer and diagnostic MRI to determine the extent of operation and radiotherapy

Lead Researcher: A/Prof. Verity Ahern

Primary Sponsor or Lead Organisation: TROG Cancer Research

Study email: Tracy.Pearl-Larson@health.nsw.gov.au

ICR-CTSU/2014/10049/TROG 14.02 RAIDER

Category B Genitourinary

Study Title: A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder

Lead Researcher: A/Prof. Farshad Foroudi

Primary Sponsor or Lead Organisation: ICR (TROG)

Study email: RAIDER@trog.com.au

EORTC-1219 ROG-HNCG/TROG 14.03

Category B Head & Neck

Study Title: A blind randomized multicentre study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15-gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck.

Lead Researcher: Dr. Howard Liu

Primary Sponsor or Lead Organisation: EORTC (TROG)

Study email: EORTC1219@trog.com.au

EORTC 1308/TROG 15.02 ROAM

Category B CNS

Study Title: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial

Lead Researcher: Dr. Nedi Haghighi

Primary Sponsor or Lead Organisation: EORTC (TROG)

Study email: ROAM@trog.com.au

TROG 15.03/ANZUP 16.001 FASTRACK II

Category A Genitourinary

Study Title: Focal Ablative STereotactic RADiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Lead Researcher: Prof. Shankar Siva

Primary Sponsor or Lead Organisation: TROG Cancer Research

Study email: FASTRACKII@trog.com.au

ICR-CTSU/2015/10052/TROG 16.03 CORE

Category B Multiple

Study Title: A randomised trial of Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

Lead Researcher: A/Prof. Farshad Foroudi & A/Prof. David Pryor

Primary Sponsor or Lead Organisation: ICR (TROG)

Study email: CORE@trog.com.au

TROG 17.02 OUTRUN

Category A Lung

Study Title: Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases

Lead Researcher: Dr. Yu Yang Soon, A/Prof. Chee Lee & Dr. Fiona Hegi-Johnson

Primary Sponsor or Lead Organisation: TROG Cancer Research

Study email: OUTRUN@trog.com.au

other

Trials with TROG Involvement & Support

ANZ 1601/BIG 16-02 (16.04) EXPERT

Breast

Study Title: A randomised phase III trial of adjuvant radiotherapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised low-risk luminal A early breast cancer

Lead Organisation: Breast Cancer Trials (BCT)

Status: Recruiting

AGITIG (21.03) RESOLUTE

Gastrointestinal

Study Title: Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Lead Organisation: Australasian Gastro-Intestinal Trials Group (AGITG)

Status: Recruiting

CTC 0245/AGITG AG0118PS (18.04) MASTERPLAN

Gastrointestinal

Study Title: Randomised phase II study from the AGITG Mfolfinox And STereotactic Radiotherapy for Pancreatic cancer with Locally AdvANced disease

Lead Organisation: Australasian Gastro-Intestinal Trials Group (AGITG)

Status: Recruiting

AGITG AG0407GR (08.08) TOPGEAR

Gastrointestinal

Study Title: A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemo therapy for resectable gastric cancer.

Lead Organisation: Australasian Gastro-Intestinal Trials Group (AGITG)

Status: In follow-up

ANZUP 1801 (21.02) DASL-HiCaP

Genitourinary

Study Title: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Lead Organisation: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Status: Recruiting

ANZUP 1303 (14.01) ENZARAD

Genitourinary

Study Title: Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer

Lead Organisation: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Status: In follow up

ANZGOG 1910/2020 (21.04) ADELE

Gynaecological

Study Title: Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk Endometrial cancer: a randomised phase 2 trial

Lead Organisation: Australia New Zealand Gynaecological Oncology Group (ANZGOG)

Status: Recruiting

CKTO 2006-04 (08.04) PORTEC-3

Gynaecological

Study Title: Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma

Lead Organisation: Australia New Zealand Gynaecological Oncology Group (ANZGOG)

Status: In follow up

MASC 03.18 (21.01) I-MAT

Skin

Study Title: Immunotherapy Merkel Adjuvant Trial

Lead Organisation: Melanoma and Skin Cancer Trials (MASC)

Status: Recruiting

R2810-ONC-1788 (17.11) CPOST

Skin

Study Title: A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma

Lead Organisation: Regeneron Pharmaceuticals

Status: Recruiting

20.03 AVATAR

Breast

Study Title: Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer

Lead Organisation: Peter MacCallum Cancer Centre

Status: In follow up

our

Sponsors

We are grateful to the following organisations for their support and sponsorship

CORPORATE PARTNERS



MAJOR FUNDING BODIES



Australian Government
Cancer Australia

SUPPORTER



Mater Newcastle

SOFTWARE PARTNERS



ANNUAL SCIENTIFIC MEETING SPONSORS

PLATINUM SPONSORS



SOCIAL FUNCTION SPONSORS



WORKSHOP SPONSORS



BRONZE SPONSORS



LANYARD



APP SPONSOR



RADIOSURGERY GLOBAL

AWARD SPONSOR



EXHIBITOR





Experience the difference

We don't just build technology, **we build hope**



[elekta.com](https://www.elekta.com)

ARIA CORE



Finally, a complete **continuum**
of care for all of oncology.

One solution. Endless possibilities. The single, seamless,
connected system to actively manage patient information
and drive workflows—**a new dimension in oncology care.**

varian
A Siemens Healthineers Company



©2024 Varian Medical Systems, Inc. All rights reserved. VARIAN and ARIA CORE are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off. Not available for sale in all markets. Refer enquiries to Varian Medical Systems Australasia on 1800.657.036 or customerservice-anz@varian.com.

GenesisCare Research

Supporting a wide range of industry, collaborative, and investigator-initiated trials

At GenesisCare, we challenge ourselves every day to find new and better ways to treat illness and disease and deliver better outcomes for our patients. Our participation in clinical research allows us to collect high-quality clinical data to help inform treatment protocols, product development, and new therapies.



Research activity



>45
Sites/clinics



>55
Dedicated staff



>130
Active Research
Projects



>1600
Total patients
in trials

Types of research

- Industry, collaborative and investigator-initiated trials
- Medical oncology, radiation oncology, haematology, theranostics and precision medicine
- Ph 0 – IV, registries and RWD

Research in numbers – 2023

Top disease sites	Prostate, breast, lung and gastro-intestinal cancer
Principal Investigators	75
Interventional research projects	92
Observational research projects	21
External research collaborations	66
Publications	26

For information, please contact:
research@genesiscare.com





World-class cancer care, close to home

Radiation Oncology | Medical Oncology
Haematology | Clinical Trials

For us, care is more than a word - it's a promise. We proudly offer:



40+ years experience delivering cancer care



38 cancer centres [and growing]



200+ internationally recognised specialists



Australia's largest private cancer clinical trials program



No wait list for consultation or treatment



World-class technology and techniques

Icon Cancer Centre is part of Icon Group - Australia's largest dedicated cancer care provider. Our mission is strong but simple - to deliver the best cancer care possible, to as many people as possible, as close to home as possible.

Our

Committee Members

TROG would like to thank the members of all the TROG committees for their enormous efforts during the year, particularly as the majority of this work is performed on a voluntary basis.

TROG Scientific Committee (TSC)

- Sashendra Senthil (Chair)
- Yoo Young (Dominique) Lee
- Lachlan McDowell
- Peter Gorayski
- Shivani Kumar
- James Lynam
- Jonathon Tibballs
- Christopher Brown
- Paul Keall
- John Stubbs
- Richard De Abreu Lourenço (CREST)
- Brendan Mulhern (CQUEST)
- Renee Swanson
- Alisha Moore
- Rebecca Montgomery

TROG Publications Committee (TPC)

- Shivani Kumar (Chair)
- Sashendra Senthil
- Christopher Brown
- Ryan Davey

New Techniques and Technology Committee (NTTC)

- Nick Hardcastle (Chair)
- Dean Wilkinson (Deputy Chair)
- Peter Greer
- David Willis
- Michael Bailey
- Annette Haworth
- Tomas Kron
- Joerg Lehmann
- Rob McDowall
- Kenton Thompson
- John Shakeshaft
- Andrew Cousins
- Michael Jameson
- Martin Ebert
- Rhonda Brown
- Farshad Foroudi
- Ben Hindson
- Lois Holloway
- Alisha Moore
- Olivia Cook

New Techniques and Technology Committee (NTTC) – Adaptive Working Group

- Michael Jameson (Chair)
- Suzanne Lydiard (Deputy Chair)
- Alexandra Quinn (Task Group Lead)
- Chris Rumley (Task Group Lead)
- Sarah Elliot (Task Group Lead)
- Alisha Moore
- Peter Greer
- Sweet Ping Ng
- Tomas Kron
- Julie Chu
- James Korte
- Marcus Powers
- Sirisha Tadimalla
- Amy The
- Joerg Lehmann
- Benjamin Harris
- Jeremy de Leon
- Jerome Gastaldo
- Rhonda Brown
- Olivia Cook
- Sofee Holmes

New Techniques and Technology Committee (NTTC) – Image Registration Working Group

- Nick Hardcastle (Chair)
- Laurel Schmidt (Deputy Chair)
- Alisha Moore
- Michael Bailey
- Kenton Thompson
- Ben Archibald
- Joerg Lehmann
- Timothy Blacketer
- Jason Dowling
- Shrikant Deshpande
- Simon Goodall
- Olivia Cook

Secondary Data Analysis Committee (SDAC)

- Martin Ebert (Chair)
- Sweet Ping Ng
- Stuart Greenham
- Richard De Abreu Lourenço
- Vanessa Panettieri
- Kenton Thompson
- Val Gebski
- Michael Bailey
- Lois Holloway
- Tracy Pearl-Larsson
- Dione Liefman
- Renee Swanson
- Alisha Moore
- Sofee Holmes

Finance Audit & Risk Management Committee

- Dr. Tim Kuypers, (Chair)
- Dr. Fiona Hegi-Johnson
- Mrs. Sue Naeyaert
- Mr. Andrew Beck

Independent Data and Safety Monitoring Committee (IDSMC)

- Bryan Burmeister (Chair)
- Peta Forder
- Michael Michael
- Lara Best
- Paul Nguyen
- Nicolas Oddone-Baridon
- Wendy Paterson

Genitourinary Working Party (GUWP)

- Wee Loon Ong (Chair from May 2023)
- Niluja Thiru (Deputy Chair from May 2023)
- Shankar Siva (Chair until May 2023)
- Stephen Chin (Deputy Chair until May 2023)
- Alison Brown
- Charles Lin
- David Pryor
- Farshad Foroudi
- Michael Huo
- Muhammad Ali
- Paul Keall
- Robyn Cheuk
- Eric Wegener
- Suki Gill
- Shreya Armstrong
- Rebecca Montgomery
- Jessica Piotrowski

Lung Working Party (LWP)

- Fiona Hegi-Johnson (Chair)
- Yu Yang Soon (Deputy Chair)
- Brett Hughes
- Chris Brown
- Eric Hau
- Jane Ludbrook
- Margot Lehman
- Mark Pinkham
- Michael Macmanus
- Sagun Parakh
- Shalini Vinod
- Susan Ann McCullough
- Tao Mai
- Tomas Kron
- Wen Xu
- Rebecca Montgomery
- Jessica Piotrowski

Breast Working Party (BWP)

- Farshad Foroudi (Chair)
- Tomas Kron (Deputy Chair)
- Boon Chua
- Chia May Wong
- Jenna Dean
- Joerg Lehmann
- Kylie Jung
- Melissa James
- Robyn Cheuk
- Steven David
- Janice Yeh
- Vikash Patel
- Anelyn Chui
- Rebecca Montgomery
- Jessica Piotrowski

Head Neck and Skin Working Party (HNSWP)

- Charles Lin (Chair)
- Lachlan McDowell (Deputy Chair)
- Albert Tiong
- Andrew Macann
- Annette Lim
- Anzela Anzela
- Brett Hughes
- Chris Wratten
- Clare Bajraszewski
- Daniel Xing
- Danny Rischin
- Dione Liefman
- Farhannah Aly
- Howard Liu
- James Sandison
- Joe Chang
- June Corry
- Liz Kenny
- Margaret Chua
- Rahul Ladwa
- Sandro Porceddu
- Sweet Ping Ng
- Thanuja Thachil
- Tsien Fua
- Lessandra Yan Shan Chee
- Rathan Subramaniam
- Eric Wegener
- Puma Sundaresan
- Bruce Ashford
- Rebecca Montgomery
- Jessica Piotrowski

Central Nervous System Working Party (CNSWP)

- Mark Pinkham (Chair)
- Kylie Jung (Deputy Chair)
- Alexandre Santos
- Andrew Pullar
- Andrew Scott
- Claire Phillips
- Dione Liefman
- Eng-Siew Koh
- Frank Saran
- Hien Le
- John Ryan
- John Shakeshaft
- Joseph Sia
- Senthilkumar Gandhidasan
- Shona Edwards
- Sagun Parakh
- Wee Loon Ong
- Peter Gorayski
- Rebecca Montgomery
- Jessica Piotrowski

Particle Therapy Special Interest Group

- Hien Le (Chair)
- Jonathan Sykes (Secretary)
- Annette Haworth
- Adam Yeo
- Alexandre Santos
- Colin Hornby
- David Thwaites
- Debra Vincent
- Felicity Height
- Jason Wasiak
- Joshua Dass
- Julie Chu
- Kelly Skelton
- Lisa Hall
- Liz Kenny
- Martin Ebert
- Michael Penniment
- Michaela Short
- Michelle Li
- Penny Mackenzie
- Peter Gorayski
- Scott Penfold
- Sweet Ping Ng
- Verity Ahern
- Alisha Moore
- Alana Rossi
- Angela Whitehead
- Sofee Holmes
- Rachael Dykyj

MR in RT Special Interest Group

- Farshad Foroudi (Chair)
- Trang Pham (Deputy Chair)
- Alex Tan
- Peter Greer
- Dion Forstner
- Sarah Elliot
- Paul Keall
- Alisha Moore
- Kate Skehan
- Stacey Alvares
- Jonathan Goodwin
- Benjamin Harris
- Suzanne Lydiard
- James Korte
- Kate Francis
- Margaret Cokelek
- Joel Parker
- Kerryn Brown
- Shivani Kumar
- Rachel Doyle
- Hannah Hickling
- Milad Mirzaei
- Amy Brown
- Katelyn Cahill
- Laura O'Connor
- Muralidas Ramanathan
- Salman Zanjani
- Stephen Chin
- Sweet Ping Ng
- Julie Chu
- Shalini Vinod
- Chris Rumley
- Jeremiah De Leon
- Roshini Gunewardena
- Chris Rumley
- Glenn Cahoon
- Jenna Dean
- Niluja Thiru
- Sarah Porter
- Sarah Elliott
- Joerg Lehmann
- Peter Greer
- Sirisha Tadimalla
- Benjamin Harris
- Belinda Campbell
- Kerryn Brown
- Lois Holloway
- Margaret Cokelek
- Alana Rossi
- Angela Whitehead
- Olivia Cook
- Sofee Holmes

Annual Scientific Meeting Organising Committee

- Hien Le (Co-Convenor)
- Kelly Skelton (Co-Convenor)
- Lydia Tamblyn (Co-Convenor)
- Susan Goode
- Courtney Wheeler

2023 ASM Program Committee

- Hien Le
- Kelly Skelton
- Lydia Tamblyn
- Tomas Kron
- Lachan McDowell
- Wee Loon Ong
- Yu Yang Soon
- Andy Cousins
- Renee Swanson
- Rebecca Montgomery
- Alisha Moore
- Susan Goode
- Courtney Wheeler

2023 Clinical Research Education Workshop (CREW) committee

- Bianca Karle (Chair)
- Sue McCullough
- Adrienne See
- Xiaolu Wang
- Jayd Lynch
- Amber Murray
- Kelly Skelton (convenor)
- Mitchell Peters
- Cate Davey
- Renee Swanson
- Jackie Buck

2023 Technical Research Workshop (TRW) Committee

- Laurel Schmidt (Chair)
- Joerg Lehmann (Co-Chair)
- Jenna Dean
- Fahim Siddiqi
- Rob McDowall
- Tomas Kron
- Nick Hardcastle
- Dean Wilkinson
- Narelle Wallace
- John Kipritidis
- Stephanie Keehan
- Julia Green
- Suzanne Lydiard
- Scott Penfold
- Johnson Yuen
- Mahesh Chandroth
- Alisha Moore
- Olivia Cook
- Sarah Porter
- Rachael Dykyj
- Sofee Holmes

The logo for TROG Cancer Research features the word 'TROG' in a bold, sans-serif font. The 'T', 'R', and 'G' are dark blue, while the 'O' is bright orange. Above and below the 'O' are three small dark blue dots. Below 'TROG' is a thin horizontal line, followed by the words 'CANCER' and 'RESEARCH' stacked vertically in a bold, orange, sans-serif font.

TROG
CANCER
RESEARCH

POSTAL

PO Box 88 Waratah
NSW 2298

OFFICE

Level 5, MHA Building, Calvary Mater Newcastle,
Edith Street Waratah NSW 2298

EMAIL

General: trog@trog.com.au

Membership: membership@trog.com.au